Answers are grounded in this paper and cite their sources.
Recent advances in the serological analysis of recombinant cDNA expression libraries and proteomic analysis have enabled the identification of numerous kinds of novel autoantigens, especially tumor-associated antigens (TAAs). The emergence of antibodies to TAAs might imply that an autoimmune response was involved in the malignant transformation. These autoantibodies to TAAs often have predictive value as well as diagnostic relevance. Similarly, the relationship between autoimmunity and metabolic abnormalities, including insulin resistance and hepatic steatosis, has been also documented. Metabolic abnormalities are frequently associated with autoimmune diseases. In contrast, autoimmune reactions were occasionally involved in the process of metabolic dysregulation. This review primarily focuses on the current trends for the relationship between autoimmunity and cancer or metabolic abnormalities in liver disease and the current interpretations of autoantibodies in those diseases.
No takes yet. Share an insight, caveat, or question.
Himoto et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: